1417162-36-7

1417162-36-7 structure

Name: RI-2
Chemical Name: 1-(3,4-dichloro-phenyl)-3-(4-methoxy-phenyl)-4-morpholin-4-yl-pyrrole-2,5-dione
CAS Number: 1417162-36-7
Molecular Formula: C₂₁H₁₈Cl₂N₂O₄
Molecular Weight: 433.285
Catalog: Signaling Pathways Cell Cycle/DNA Damage RAD51
Create Date: 2018-05-20 03:34:21
Modify Date: 2025-08-25 10:32:53
RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.

Name	1-(3,4-dichloro-phenyl)-3-(4-methoxy-phenyl)-4-morpholin-4-yl-pyrrole-2,5-dione
Synonyms	1H-Pyrrole-2,5-dione, 1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-(4-morpholinyl)- 1-(3,4-Dichlorophenyl)-3-(4-methoxyphenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione RI-2

Description	RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> RAD51 Research Areas >> Cancer
Target	IC50: 44.17 μM (RAD51)[1]
In Vitro	RI-2 (7a) is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM. RI-2 specifically inhibits homologous recombination repair in human cells. RI-2 (150 μM) induces a significant sensitization of cells[1].
Cell Assay	HEK293 cells are plated into 96-well tissue culture plates at a density of 300 cells per well in the presence or absence of 50 nM mitomycin C (MMC) for 24 hours at 37°C, 5% CO2. Media is subsequently replaced with fresh media containing 0.5% DMSO plus RI-2 for an additional 24 hours. RI-2 is then removed, and cultures are allowed to grow to a 50-70% confluence. Average survival from at least three replicates is measured using CellGlo reagentor. RI-2 is deemed successful in sensitizing cells to MMC if they generate significantly greater toxicity in the presence of MMC relative to the absence of MMC. Specifically, sensitization is scored as a “+” when non-overlapping standard errors are observed for at least two pairs of compound doses[1].
References	[1]. Budke B, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10;56(1):254-63.